Overview

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

Status:
Completed
Trial end date:
2016-05-30
Target enrollment:
Participant gender:
Summary
The primary objective for this study is to evaluate the safety of lebrikizumab compared with Topical Corticosteroids (TCS) alone in patients with persistent moderate to severe Atopic Dermatitis (AD) that is inadequately controlled with TCS.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Antibodies, Monoclonal
Hydrocortisone
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide